Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PKM | P14618 | 3/20 | 1.00 |
| ▸ | MAPT | P10636 | 4/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.42 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.42 |
| ▸ | GRK5 | P34947 | 1/20 | 0.42 |
| ▸ | LIMK1 | P53667 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 3/20 | 0.37 |
| ▸ | BLM | P54132 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2386652 | 0.79 | PKM (0.66) | PKMMAPTALDH1A1KDM4ETDP1 | |
| SCHEMBL6920167 | 0.77 | PKM (0.59) | PKMMAPTALDH1A1KDM4ETDP1 | |
| SCHEMBL38665911 | 0.76 | PKM (0.61) | PKMMAPTALDH1A1KDM4ETDP1 | |
| SCHEMBL4501944 | 0.76 | PKM (0.61) | PKMMAPTALDH1A1KDM4ETDP1 | |
| SCHEMBL13626328 | 0.76 | PKM (0.61) | PKMMAPTALDH1A1KDM4ETDP1 | |
| SCHEMBL2386649 | 0.76 | PKM (0.61) | PKMMAPTALDH1A1KDM4ETDP1 | |
| SCHEMBL1730 | 0.76 | PKM (0.61) | PKMMAPTALDH1A1KDM4ETDP1 | |
| SCHEMBL3373070 | 0.76 | PKM (0.61) | PKMMAPTALDH1A1KDM4ETDP1 | |
| SCHEMBL7113070 | 0.76 | PKM (0.61) | PKMMAPTALDH1A1KDM4ETDP1 | |
| SCHEMBL28693875 | 0.76 | PKM (0.61) | PKMMAPTALDH1A1KDM4ETDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090270367-A1 | SUBSTITUTED HYDROXYETHYLAMINE ASPARTYL PROTEASE INHIBITORS | ELAN PHARMACEUTICALS, INC. | 2009-10-29 | — | — | US | claimed |
| EP-1730125-A2 | SUBSTITUTED HYDROXYETHYLAMINE ASPARTYL PROTEASE INHIBITORS | ELAN PHARMACEUTICALS, INC. (US) | 2006-12-13 | — | — | EP | claimed |
| US-20050239836-A1 | Substituted hydroxyethylamine aspartyl protease inhibitors | ELAN PHARMACEUTICALS, INC. | 2005-10-27 | — | — | US | claimed |
| WO-2005087751-A2 | SUBSTITUTED HYDROXYETHYLAMINE ASPARTYL PROTEASE INHIBITORS | ELAN PHARMACEUTICALS, INC. (US) | 2005-09-22 | — | — | WO | claimed |
| WO-2004043417-A2 | COMPOSITION FOR DYEING KERATIN FIBRES CONTAINING A DYE PRECURSOR AND AN ENZYME WITH NITROREDUCTASE ACTIVITY | L'OREAL (FR) | 2004-05-27 | — | — | WO | claimed |
| US-20230212167-A1 | METHOD FOR SYNTHESIZING ANTI-TUMOR COMPOUND AND INTERMEDIATES THEREOF | TRANSTHERA SCIENCES (NANJING), INC. (CN) | 2023-07-06 | — | — | US | disclosed |
| EP-4015511-A1 | OXIDATION CATALYSTS BASED ON MACROCYCLIC COMPOUNDS | CARNEGIE MELLON UNIVERSITY (US) | 2022-06-22 | — | — | EP | disclosed |
| CN-113912542-A | Method for directly ammoniating nitro nitrogen heterocyclic compound | 南京理工大学 | 2022-01-11 | — | — | CN | disclosed |
| WO-2004043417-A2 | COMPOSITION FOR DYEING KERATIN FIBRES CONTAINING A DYE PRECURSOR AND AN ENZYME WITH NITROREDUCTASE ACTIVITY | L'OREAL (FR) | 2004-05-27 | — | — | WO | disclosed |
| EP-0375977-A1 | Oxidation hairdyeing composition based upon diaminopyrazole derivatives, and these diaminopyrazole derivatives | Wella Aktiengesellschaft (DE) | 1990-07-04 | — | — | EP | disclosed |
| US-4650861-A | RED SHADES ON HYDROPHOBIC TEXTILES | CIBA-GEIGY CORPORATION (US) | 1987-03-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230212167-A1 | METHOD FOR SYNTHESIZING ANTI-TUMOR COMPOUND AND INTERMEDIATES THEREOF | SQLE, HCCS, DHPS | PKM 363/4885MAPT 2102/4885ALDH1A1 1276/4885 |
| US-20090270367-A1 | SUBSTITUTED HYDROXYETHYLAMINE ASPARTYL PROTEASE INHIBITORS | DNPEP, MME, ANPEP | PKM 1999/4885MAPT 249/4885ALDH1A1 1971/4885 |
| US-20050239836-A1 | Substituted hydroxyethylamine aspartyl protease inhibitors | DNPEP, MME, ANPEP | PKM 1999/4885MAPT 249/4885ALDH1A1 1971/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.